CEO John Baker describes how the project, done in collaboration with Ultima Genomics and Waters Corporation, will give researcher a tool to better understand the immune system. He also describes how IMU's blood sample based system works, and how it has been used for things such as to better understand which patients will respond to cancer immunotherapies.

CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.

They discuss recent advances, what's ahead, Cigall's work in epigenetics, and how a new hospital will be purpose built for patients with the best new technologies in clinical research.

From the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in Alzheimer's, and how he plans to invest for the future.

He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.

CEO Markus Warmuth walks us through the data and provides a broader update on the pipeline progress at Monte Rosa and for the field of degraders and molecular glues more broadly.

CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.

Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.

CEO David Veitch discusses Cresemba and Zevtera, both of which have momentum in what used to be market with structural barriers to commercial success, but no longer are in most geographies. Plus, a key phase 3 that will read out for Basilea's next mold infection program, fosmanogepix, in 2028.

Chris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to achieve its primary endpoint.